Septerna to Present at TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Septerna (Nasdaq: SEPN) announced that CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 p.m. ET in Boston.
A live webcast will be available on the company investor website and will be archived for at least 30 days for on-demand viewing.
Positive
- None.
Negative
- None.
News Market Reaction – SEPN
In the Feb 24 session, SEPN gained 10.21%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.0% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Inducement option grant | Neutral | -1.4% | Inducement stock option grant to new Chief Legal Officer under Nasdaq rule. |
| Feb 10 | Clinical data presentation | Positive | +0.4% | Announcement of Phase 1 SEP-631 data presentation at 2026 AAAAI meeting. |
| Jan 08 | Leadership appointment | Positive | -1.7% | Appointment of industry veteran Mark A. Wilson as Chief Legal Officer. |
| Dec 17 | JP Morgan conference | Neutral | +1.2% | Planned CEO presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 25 | Evercore conference | Neutral | -1.9% | Participation in fireside chat at 8th Annual Evercore Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has mostly involved conferences, leadership changes, and equity awards. Price reactions have been modest and sometimes moved opposite to seemingly constructive updates, suggesting limited but occasionally contrarian trading around routine corporate news.
This announcement continues a pattern of visibility and corporate updates for Septerna. Recent items include multiple stock option grants on February 6, 2026, a leadership expansion with a new Chief Legal Officer on January 8, 2026, and participation in high-profile conferences such as the 44th Annual J.P. Morgan Healthcare Conference and the 8th Annual Evercore Healthcare Conference. Price moves around these events were generally modest, indicating that the market has treated them as incremental rather than transformational.
Key Terms
g protein-coupled receptor medical
gpcr medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston.
A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
